Heart disease, diabetes, high blood pressure, high cholesterol, lung disease — these chronic conditions don't get cured. They just get "managed" with a pill you take every single day, without a break. That means one patient is a customer who comes back to buy, every month, for the next ten or twenty years. And as society ages, the patient base grows on its own, no matter what the economy does. This is the story of the "chronic-disease drug franchise" — durable, predictable revenue, right up until the day the patent expires and the whole thing vanishes.
Contains
Theme index· base 100 · USD total return
Why is Chronic-Disease Pharma Franchises moving?
Latest
▲2
Chronic-disease franchises grow on demand, deals, and new approvals
▲
Chronic-disease demand stays strong Ironwood raised 2026 revenue guidance on Linzess demand, J&J lifted its outlook after 6.6% sales growth, and Lilly's consensus estimates rose on 48% revenue growth. These show chronic-disease medicines are still selling well, supporting the theme.
Shows the core demand driver for chronic-disease franchises remains intact.
New approvals and deals widen treatment options Bayer won FDA acceptance for KERENDIA in non-diabetic kidney disease, Viatris agreed to buy Pacira for $1.65 billion to add non-opioid pain drugs, and Lilly's Taltz plus Zepbound showed broader biomarker changes. These expand chronic-disease franchises.
Highlights new growth avenues and portfolio expansion in chronic disease.
Pricing and competition pressure GLP-1 leaders Citi cut Novo Nordisk's target on flat margins and pricing pressure, while Novo raised its outlook but faces competition from Lilly. Lilly trades at a discount to its history despite growth. This tug-of-war affects the theme.
Shows the main counterweight: pricing and competition even as demand grows.
340B rebate pilot adds regulatory uncertainty The Trump administration picked 10 drugmakers, including AbbVie, Amgen, Pfizer, and GSK, for a 340B rebate pilot starting January 1. It changes how discounts are paid, creating uncertainty for chronic-disease drug pricing and hospital partnerships.
A new regulation that could affect drugmakers' pricing and revenue in the chronic-disease space.
Bayer Wins FDA Acceptance for KERENDIA CKD Filing Without Diabetes
Bayer reported that the U.S. FDA accepted its supplemental New Drug Application for KERENDIA for chronic kidney disease patients without diabetes. The filing is backed by Phase III trial data that Bayer says showed kidney and cardiovascular benefits in non diabetic CKD patients, and KERENDIA is already approved in the U.S. for adults with chronic kidney disease associated with type 2 diabetes. The sNDA covers adults with CKD without diabetes on standard care, a population not included in KERENDIA's current U.S. approvals, and the FIND CKD trial enrolled 1,584 such patients and showed a statistically significant 0.7 mL/min/1.73 m²/year difference in eGFR decline versus placebo, plus a benefit on a kidney cardiovascular composite outcome. Bayer, a €41.8 billion life science group active across Europe, the Americas and Asia, has been pushing deeper into prescription therapies, and the company's narrative highlights new labels and approvals for KERENDIA as a key pharmaceutical catalyst that can help offset patent losses. The critical signpost now is the FDA's decision on this sNDA, including the timing and any label wording around the kidney and cardiovascular endpoints from FIND CKD.
Johnson & Johnson Q3 Earnings Preview: Estimates Cut, Stelara Biosimilar Pressure Looms
Johnson & Johnson will report its third-quarter 2026 results on Oct. 13, with the Zacks Consensus Estimate pegged at $25.37 billion in sales and $2.66 per share in earnings. Over the past 60 days, the consensus estimate for 2026 earnings has declined from $11.48 to $11.21 per share, while the 2027 estimate has fallen from $12.81 to $12.17. J&J has an Earnings ESP of +2.10% and a Zacks Rank #3 (Hold), and it exceeded earnings expectations in each of the trailing four quarters, delivering an average surprise of 1.39%. Within the Innovative Medicine segment, consensus estimates stand at $4.33 billion for Darzalex, $2.24 billion for Tremfya and $1.07 billion for Erleada, while Stelara sales are seen at $634.0 million and Imbruvica at $602.0 million, with Stelara's loss of exclusivity having cut the segment's growth by 760 basis points in the second quarter. The MedTech segment carries a consensus estimate of $8.77 billion, and J&J still expects to generate more than $100 billion in revenues in 2026 after $49.4 billion in the first half.
Aging Population › Chronic-Disease Pharma Franchises ▼Demand
Biotech & Genomic Medicine › Autoimmune & Immunology Therapeutics Demand
Biotech & Genomic Medicine › Oncology Therapeutics Demand
JNJ · Capital · Negative Consensus 2026/2027 EPS estimates cut ahead of Q3 report, with Stelara loss of exclusivity dragging Innovative Medicine growth.
AbbVie Revenue Rises 10.2% as Skyrizi and Rinvoq Offset Humira's 35.9% Decline
AbbVie grew total revenue 10.2% to $16.99 billion last quarter even as Humira sales fell 35.9% to $756 million, with the company's newer immunology drugs carrying the growth. Skyrizi brought in $5.505 billion, up 24.4%, and Rinvoq added $2.525 billion, up 24.5%, lifting total immunology sales to $8.786 billion, up 15.1%. Neuroscience contributed $3.228 billion, up 20.3%, while oncology slipped 1.5% to $1.650 billion and aesthetics edged up 0.3% to $1.282 billion. Adjusted earnings per share came in at $3.65, up 22.9%, against GAAP earnings of $2.03, and management guides to full-year adjusted EPS of $13.87 to $14.07. AbbVie recently closed its purchase of Apogee Therapeutics at $135.11 per share in cash, for a total equity value of $10.9 billion, a deal the company says will reduce adjusted EPS by $0.14 this year and approximately $0.46 in 2027, with accretion beginning in 2032. At a forward P/E of 18.97 as of October 6, AbbVie trades essentially in line with the sector's 18.84 but above its own five-year average of 14.51, a premium that leans on expected EPS growth of 16.14% in 2027.
Novo Nordisk Raises 2026 Outlook, Targets Peer-Level Growth Through 2030
Novo Nordisk raised its 2026 outlook while telling investors at a London strategy day that it aims to grow revenue through 2030 at roughly the pace of large drugmaker peers. In the second quarter of 2026, adjusted sales rose 7% at constant exchange rates and adjusted operating profit rose 11%, though reported operating profit fell 16%, dragged down by a DKK 6.3 billion non-cash impairment on pipeline assets and by a year-ago rebate reversal. The raised 2026 outlook now puts adjusted sales and operating profit between flat and down 6% at constant exchange rates, while the longer view promises more than five multi-blockbuster launches by 2030, over DKK 150 billion in pipeline sales in 2035, and revenue growth in line with peers from 2026 to 2030, which management stressed are ambitions rather than guidance. The company's Wegovy pill topped 265,000 weekly prescriptions in a single week this summer and total prescriptions have passed 5 million since launch, but Eli Lilly's Mounjaro and Zepbound have overtaken Ozempic and Wegovy in the US, and Novo's next-generation shot CagriSema missed its goal of proving it was not inferior to Lilly's tirzepatide. At a forward P/E of 10.97 as of October 6, against 18.77 for the sector and a five-year average of 27.91, Novo trades well below peers, with 59 hedge funds holding the stock in the most recent quarter, up from 55, and short interest at just 0.83% of the float.
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity Competition
Aging Population › Chronic-Disease Pharma Franchises Competition
Longevity & Life Extension › GLP-1 Healthspan Proxies Competition
NVO · Capital · Neutral Novo raised its 2026 outlook and reported Q2 adjusted sales +7% and operating profit +11%, but reported operating profit fell 16% on a DKK 6.3bn impairment and the outlook still implies flat-to-down adjusted sales/profit.
NVO · Competition · Negative Eli Lilly's Mounjaro and Zepbound have overtaken Ozempic and Wegovy in the US, and Novo's next-gen CagriSema missed its non-inferiority goal versus Lilly's tirzepatide.
LLY · Competition · Positive Eli Lilly's Mounjaro and Zepbound have overtaken Ozempic and Wegovy in the US, and CagriSema missed its non-inferiority goal versus Lilly's tirzepatide.
Eli Lilly Trades at 30.94 Times Forward Earnings Despite 48% Revenue Growth
Eli Lilly reported 48% revenue growth for the second quarter of 2026 and raised its full-year outlook, yet the stock trades at 30.94 times forward earnings, well below its five-year average of 45.59. Mounjaro brought in $9.9 billion in the quarter, up 91%, and Zepbound added $4.9 billion, up 46%, while non-GAAP gross margin reached 86.3% and revenue outside the US rose 80% to $8.6 billion. The once-daily weight-loss pill Foundayo booked $98 million in its first quarter of sales, and Medicare's new coverage pathway now lets eligible patients get Foundayo or Zepbound for $50 a month, with Lilly estimating about 20 million Medicare patients may meet the clinical criteria. Management lifted 2026 revenue guidance to between $85 billion and $87 billion from $82 billion to $85 billion, and plans to file retatrutide with the FDA in the first quarter of 2027. Growth was volume-led, with volume up 60% against a 13% decline in realized prices, and second-quarter EPS of $8.38 absorbed $3.03 per share of acquired research charges, while reported EPS was $7.94 and full-year guidance stands at $35.50 to $36.50.
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity ▲Demand
Aging Population › Chronic-Disease Pharma Franchises ▲Demand
Longevity & Life Extension › GLP-1 Healthspan Proxies ▲Demand
LLY · Capital · Positive Lilly reported 48% Q2 revenue growth, 86.3% gross margin, and raised full-year 2026 revenue guidance to $85-87B.
LLY · Demand · Positive Mounjaro sales rose 91% to $9.9B, Zepbound rose 46% to $4.9B, and Medicare's new coverage pathway opens Foundayo/Zepbound to ~20M eligible patients.
Eli Lilly Consensus Estimates Rise as Zacks Rank Holds at #3
Eli Lilly is expected to post earnings of $9.83 per share for the current quarter, a year-over-year change of +40%, with the Zacks Consensus Estimate edging up +0.1% over the last 30 days. For the current fiscal year, the consensus earnings estimate of $36.64 points to a change of +51.3% from the prior year and has risen +0.3% over the past month, while the next fiscal year's consensus estimate of $46.8 indicates a change of +27.7% and has moved +1.4% higher. On the revenue side, the consensus sales estimate of $22.14 billion for the current quarter points to a year-over-year change of +25.8%, with the $88.88 billion and $102.02 billion estimates for the current and next fiscal years indicating changes of +36.4% and +14.8%, respectively. In the last reported quarter, Lilly posted revenues of $22.97 billion, up +47.7% year over year, and EPS of $8.38 versus $6.31 a year ago, beating the Zacks Consensus revenue estimate of $20.26 billion by +13.38% and the EPS estimate by +39.43%. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Lilly, and the stock is graded D on the Zacks Value Style Score, indicating it trades at a premium to its peers.
Aging Population › Chronic-Disease Pharma Franchises ▲Capital
Longevity & Life Extension › GLP-1 Healthspan Proxies Capital
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity ▲Capital
LLY · Capital · Positive Consensus earnings and revenue estimates for Eli Lilly rose, with current-quarter EPS seen up 40% YoY and full-year EPS up 51.3%.
Lilly's Taltz Plus Zepbound Shows Broader Biomarker Changes in Psoriasis and Obesity Trial
Eli Lilly and Company announced new exploratory data from the TOGETHER-PsO Phase 3b trial showing that concomitant use of Taltz and Zepbound produced broader biomarker changes than Taltz alone in adults with moderate-to-severe plaque psoriasis and obesity or overweight with at least one additional weight-related comorbid condition. The prespecified analysis, presented at the 2026 Fall Clinical Dermatology Conference in Las Vegas, examined circulating proteins and gene expression in the blood and found that Taltz plus Zepbound was associated with changes in more proteins, 482 versus 140 differentially expressed proteins, and more genes, 467 versus 16 differentially expressed genes, by Week 36, with broader biomarker responses emerging as early as Week 12. The combination also showed greater reductions in inflammatory immune activity than Taltz alone, including changes related to neutrophils, and changes in a subset of neutrophil-associated markers mediated a portion of the additional Psoriasis Area and Severity Index response. The data follow previously reported TOGETHER-PsO results showing superior skin clearance and clinically meaningful weight reduction with the combination versus Taltz alone at the Week 36 primary endpoint, maintained or further improved through Week 52, with safety consistent with the known profile of each medicine. In the U.S., approximately 61% of people with psoriasis also have obesity or overweight with at least one weight-related comorbidity.
Biotech & Genomic Medicine › Autoimmune & Immunology Therapeutics ▲Technology
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity ▲Technology
Aging Population › Chronic-Disease Pharma Franchises ▲Technology
LLY · Technology · Positive New TOGETHER-PsO Phase 3b biomarker data show Taltz plus Zepbound produced broader biomarker and inflammatory changes than Taltz alone, supporting the combination's clinical profile.
Citi cuts Novo Nordisk price target to 296 crowns on flat margin outlook
Citi Research lowered its price target on Novo Nordisk to 296 Danish crowns from 310, citing company guidance for broadly stable margins through 2030 that leaves little room for margin growth. The rating was kept at neutral. The guidance, driven by research and development spending, came at Novo's recent capital markets day, prompting Citi to cut its adjusted operating profit forecasts for 2028 to 2030 by 2% to 4%. Citi's target now assumes Novo trades at 14 times 2027 earnings, down from 15 times, and the analysts cut their expected 2027-2030 annual earnings-per-share growth rate to 9% from 12%. Citi raised its 2026 and 2027 adjusted operating profit forecasts by 2% to 3% on higher expected sales of Novo's Wegovy pill outside the United States and U.S. prescription trends for Ozempic, and lifted its adjusted sales forecasts by 3% for 2026 and 1% for 2027. At the capital markets day, Novo said improved manufacturing capacity means it intends to launch the Wegovy pill in at least 20 countries by the end of 2027, covering two-thirds of the obesity market it currently serves, and Citi raised its peak sales forecast for the pill to $13 billion from $10 billion, pointing to its UK launch where 1 million packs have been distributed since July. Ahead of Novo's third-quarter results on Nov. 4, Citi forecast sales 1% above consensus and Wegovy pill sales 16% above it at kr5.3 billion against the consensus kr4.5 billion, with adjusted operating profit in line with consensus because of lower margins from higher R&D spending. Citi forecast third-quarter sales of kr73.5 billion, down 4% at constant currency, citing a roughly kr3 billion rebate-adjustment and stocking benefit in the year-earlier quarter, continued prescription and price declines for U.S. Ozempic, generic launches in Canada and Brazil, and price declines for injectable Wegovy, and said prescription data showed no real impact from Medicare eligibility for GLP-1 drugs. It forecast adjusted operating profit up 18% at constant currency, or down about 15% excluding kr9 billion in year-earlier restructuring charges, and IFRS earnings per share of kr4.15, down 8% from a year earlier mainly on an impairment after the failure of ziltivekimab in the ZEUS trial. Citi said a Wegovy pill beat would be welcome but poor visibility on injectable Wegovy pricing and growing long-term threats from competitors were likely to keep many on the sidelines, naming Lilly's retatrutide and eloralintide, Roche's enicepatide, PFE's MET-097i and AZN's elecoglipron.
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity ▼Pricing
Aging Population › Chronic-Disease Pharma Franchises ▼Pricing
Longevity & Life Extension › GLP-1 Healthspan Proxies ▼Pricing
NVO · Capital · Negative Citi cut its Novo Nordisk price target to 296 crowns and lowered 2028-2030 operating profit and EPS growth forecasts on flat margin guidance.
Viatris Agrees to Buy Pacira BioSciences in US$1.65 Billion All-Cash Deal
Viatris has agreed to buy Pacira BioSciences in a US$1.65 billion all-cash deal, adding two patent-protected non-opioid pain medicines to its portfolio. The transaction brings higher margin pain drugs and fresh expectations to Viatris, which last closed at $17.44. Viatris shares have logged a 5.0% 1 month share price return, a 7.2% 3 month share price return, a 40.0% year to date share price return, and a 1 year total shareholder return of 80.8%. The most widely followed narrative assigns Viatris a fair value of $19.40, framing the Pacira deal inside a broader rerating story built on pipeline progress and base business steadiness. Viatris still faces pressure points, including its reliance on mature, off-patent products and ongoing integration or remediation work that could keep costs unpredictable.
Aging Population › Chronic-Disease Pharma Franchises ▲Competition
PCRX · Capital · Positive Pacira is the acquisition target in Viatris's US$1.65 billion all-cash buyout, a positive M&A event for its shareholders.
VTRS · Capital · Positive Viatris agreed to acquire Pacira for US$1.65 billion, adding higher-margin patent-protected non-opioid pain drugs to its portfolio.
J&J Raises 2026 Outlook After Q2 Sales Rise 6.6% to $25.3 Billion
Johnson & Johnson raised its 2026 outlook after second-quarter sales increased 6.6% to $25.3 billion, with adjusted EPS up 4.7% to $2.90 and full-year adjusted EPS guidance lifted to $11.60-$11.75. Management now expects reported sales of $100.8 billion-$101.4 billion, putting the company on track to cross $100 billion in annual revenue for the first time. JPMorgan raised its target to $285 from $270 on September 29 while staying Neutral, and UBS holds a Buy rating with a $320 target on above-consensus revenue and EPS estimates through 2030-2032. On the pipeline side, BofA raised its peak psoriasis sales estimate for ICOTYDE to $4.5 billion from $2.4 billion on September 29, lifting expected market share to 18% from 10%, after ICOTYDE showed sustained plaque-psoriasis skin clearance through Week 112 in data released October 2. The company ended the second quarter with approximately $21 billion in cash and marketable securities against $49 billion of debt, and year-to-date free cash flow reached roughly $8.7 billion.
Ironwood Raises 2026 Revenue Guidance to $460-$485 Million on Linzess Demand
Ironwood Pharmaceuticals raised its 2026 total revenue guidance to $460-$485 million from a prior range of $450-$475 million, citing continued prescription demand for its sole marketed product Linzess. Ironwood's share of net profit from Linzess sales in the United States surged 72.6% year over year during the first six months of 2026, and management expects mid-single-digit demand growth for the full year. Linzess, developed and commercialized in the United States through an equal profit-and-loss partnership with AbbVie, also generates royalties for Ironwood from Astellas Pharma in Japan and AstraZeneca in China. A recent FDA approval expanding Linzess' use in pediatric patients with functional constipation, where no FDA-approved prescription pediatric therapies previously existed, adds a further growth opportunity ahead of the company's third-quarter results. Earlier this year Ironwood reduced Linzess' list price to support patient access, and management expects lower mandatory government rebates to drive higher net revenues through 2026. The Zacks Consensus Estimate for 2026 earnings per share has risen to $1.10 from $1.04 over the past 60 days.
Aging Population › Chronic-Disease Pharma Franchises ▲Demand
IRWD · Demand · Positive Ironwood raised 2026 revenue guidance on continued Linzess prescription demand, with its US profit share up 72.6% and mid-single-digit demand growth expected.
IRWD · Pricing · Positive Ironwood cut Linzess' list price to support patient access, and lower mandatory government rebates are expected to drive higher net revenues through 2026.
ABBV · Demand · Positive Linzess, commercialized in the US through an equal profit-and-loss partnership with AbbVie, sees continued prescription demand growth and a new pediatric FDA approval.
AZN.LSE · Demand · Positive AstraZeneca commercializes Linzess in China and generates royalties for Ironwood, benefiting from the drug's demand growth.
Mint Pharmaceuticals and Bayer Inc. Expand Canadian Distribution Partnership
Mint Pharmaceuticals Inc. has expanded its distribution partnership with Bayer Inc. in Canada to cover a broader range of Bayer medicines. The agreement adds ANGELIQ, CLIMARA 25, CLIMARA 50 and CLIMARA 75, TRIQUILAR 21 and TRIQUILAR 28, and XARELTO to a collaboration originally established for the Canadian distribution of Bayer's ADALAT XL, an antihypertensive and antianginal medicine. The addition extends the partnership across cardiovascular and women's health portfolios while maintaining the companies' focus on dependable supply and continuity of care. Mint Pharmaceuticals CEO Jaiveer Singh said the expansion lets the company apply its resilient supply chain and nationwide distribution capabilities across a broader portfolio, and Bayer Inc. Canada President and CEO Viktoria Friedrich said the broader partnership leverages Mint's Canadian distribution network and market expertise. Mint Pharmaceuticals is a Canadian-owned generic manufacturer that says it has averted 25 national drug shortages across 16 essential medicines in the last decade, and Bayer reported sales of 45.6 billion euros in fiscal 2025.
Aging Population › Chronic-Disease Pharma Franchises ▲Supply
BAYN.XETRA · Demand · Positive Bayer expands its Canadian distribution partnership with Mint to cover a broader range of Bayer medicines including XARELTO and women's health products, extending product reach.
Novo Nordisk Rated Zacks Rank #3 as Earnings Estimates Rise
Novo Nordisk is rated Zacks Rank #3 (Hold), with the Zacks Consensus Estimate for the current quarter rising 6.9% over the last 30 days to $0.80 per share, a year-over-year change of -21.6%. For the current fiscal year, the consensus earnings estimate of $3.53 points to a change of -10.9% from the prior year and has moved +2.4% over the last 30 days, while the next fiscal year's estimate of $3.41 indicates a -3.5% change and has slipped -0.3% over the past month. Consensus sales estimates stand at $11.41 billion for the current quarter, $46.1 billion for the current fiscal year and $47.16 billion for the next fiscal year, indicating changes of -2.8%, -1.5% and +2.3%, respectively. In the last reported quarter, Novo Nordisk posted revenues of $12.21 billion, up 4.5% year over year and an 8.34% surprise over the Zacks Consensus Estimate of $11.27 billion, with EPS of $0.96 versus $0.97 a year ago and a +17.07% EPS surprise. The stock is graded A on the Zacks Value Style Score, indicating it trades at a discount to its peers, though its Zacks Rank #3 suggests it may perform in line with the broader market near term.
Aging Population › Chronic-Disease Pharma Franchises Capital
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity Capital
Longevity & Life Extension › GLP-1 Healthspan Proxies Capital
NVO · Capital · Neutral Zacks Rank #3 (Hold) with consensus earnings estimates rising 6.9% for the current quarter but still down year over year, an analyst-valuation update.
Trump Administration Picks 10 Drugmakers for New 340B Rebate Pilot
The Trump administration has selected 10 companies, including AbbVie, Amgen, Pfizer, and GSK, for a new pilot program that tests a rebate model for drugs purchased under a federal program benefiting uninsured and low-income patients. The 340B Rebate Model Pilot takes effect on January 1 and allows the selected manufacturers to verify and pay rebates for 21 discounted drugs purchased under the government's 340B drug pricing program, rather than offering savings upfront as under the current discount model. The participating drugmakers are AbbVie, Amgen, Astellas, AstraZeneca, Bristol Myers, GSK, Merck, Pfizer, and Teva. The Health Resources and Services Administration, the HHS unit overseeing the program, said the approach helps address compliance concerns proactively rather than relying primarily on retrospective reviews, audits, and dispute resolution processes. The pilot marks the Trump administration's second attempt to overhaul the decades-old drug discount program, after a federal judge blocked HRSA's first 340B rebate pilot following a case brought by hospital groups last year.
Aging Population › Chronic-Disease Pharma Franchises Regulation
4503.JP · Regulation · Positive Astellas is one of the selected manufacturers participating in the 340B rebate pilot program.
ABBV · Regulation · Positive AbbVie is one of 10 selected manufacturers in the new 340B rebate pilot, allowing it to pay rebates after purchase rather than upfront discounts.
AMGN · Regulation · Positive Amgen is selected for the 340B Rebate Model Pilot, shifting it to a post-purchase rebate model for discounted drugs.
AZN.LSE · Regulation · Positive AstraZeneca is selected for the 340B rebate pilot, letting it verify and pay rebates rather than give upfront discounts.
BMY · Regulation · Positive Bristol Myers is among the 10 drugmakers chosen for the administration's 340B rebate pilot taking effect January 1.
GSK.LSE · Regulation · Positive GSK is named among the 10 drugmakers in the new 340B rebate model pilot taking effect January 1.
AbbVie Wins FDA Approval for Juvmo, First Selective D1/D5 Parkinson's Pill
AbbVie has secured FDA approval for Juvmo, a once-daily oral treatment for Parkinson's disease, with a commercial launch targeted for October 2026. Juvmo is the first selective D1/D5 dopamine receptor agonist that can be used both as a standalone treatment and in combination with levodopa, the current standard of care for Parkinson's symptoms. The approval expands AbbVie's Parkinson's portfolio, which already includes Vyalev and Duopa, and management expects the three therapies to collectively represent a peak-sales opportunity of more than $5 billion. Neuroscience now accounts for nearly a fifth of AbbVie's overall topline and generated $6.1 billion in revenues in the first half of 2026, up 22% year over year, with the company expecting approximately $12.7 billion in neuroscience revenues for the full year. The approval could also deliver a commercial payoff from AbbVie's approximately $8.7 billion acquisition of Cerevel Therapeutics in 2024, a deal that came under pressure after emraclidine failed in two registration-enabling phase II studies in schizophrenia and prompted a $3.5 billion impairment charge. AbbVie competes in neuroscience with Biogen, which markets Leqembi with Eisai and Zurzuvae, and Johnson & Johnson, whose portfolio is anchored by Spravato and Invega Sustenna and was strengthened by last year's acquisition of Intra-Cellular Therapies, adding Caplyta.
AbbVie Draws Investor Attention as Zacks Flags Consensus Estimates
AbbVie has landed on Zacks.com's list of the most searched stocks, drawing fresh attention to the drugmaker's near-term outlook. For the current quarter, AbbVie is expected to post earnings of $3.85 per share, a change of +107% from the year-ago quarter, while the Zacks Consensus Estimate has moved -0.1% over the last 30 days. The consensus earnings estimate of $14.05 for the current fiscal year indicates a year-over-year change of +40.5%, and the next fiscal year's consensus of $16.12 points to a change of +14.8%. On the top line, the consensus sales estimate for the current quarter of $17.36 billion indicates a year-over-year change of +10%, with current and next fiscal year estimates of $67.56 billion and $73.39 billion indicating changes of +10.5% and +8.6%. In the last reported quarter, AbbVie posted revenues of $16.99 billion, up +10.2% year over year, and EPS of $3.65 versus $2.97 a year ago, beating the Zacks Consensus Estimate of $16.81 billion by +1.07% on revenue with an EPS surprise of +0.27%. The recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for AbbVie, and the stock is graded C on the Zacks Value Style Score.
Aging Population › Chronic-Disease Pharma Franchises ▲Capital
Biotech & Genomic Medicine › Autoimmune & Immunology Therapeutics Capital
ABBV · Capital · Neutral AbbVie is the subject, drawing attention on Zacks' most-searched list with consensus estimates and a Zacks Rank #3 (Hold), a neutral analyst/valuation update.
United StatesBrazilChinaIndiaJapanSouth KoreaPuerto RicoSlovakia+2
Chronic-Disease Pharma Franchises▲6
Lilly's oral GLP-1 Foundayo linked to 57% cut in predicted type 2 diabetes risk
Eli Lilly and Company said post-hoc analyses of the ATTAIN-1 trial showed its oral GLP-1 Foundayo, or orforglipron, was associated with significant reductions in predicted 10-year risk of type 2 diabetes and cardiovascular disease in adults with obesity or overweight with a weight-related medical problem. At 72 weeks, participants taking Foundayo 5.5 mg, 9 mg and 17.2 mg showed estimated reductions in predicted type 2 diabetes risk versus placebo of 45.0%, 50.0% and 57.0%, respectively, while those taking Foundayo 17.2 mg also showed an estimated 18.0% reduction in predicted cardiovascular disease risk versus placebo. The findings were published in Diabetes, Obesity and Metabolism. Thomas Seck, M.D., senior vice president of product development at Lilly Cardiometabolic Health, said the analyses showed Foundayo was associated with a lower predicted long-term risk of both conditions in addition to meaningful weight loss, and that treating obesity and reducing downstream consequences can meaningfully lower healthcare costs. ATTAIN-1 was a Phase 3, 72-week, randomized, double-blind, placebo-controlled trial that randomized 3,127 participants across the U.S., Brazil, China, India, Japan, South Korea, Puerto Rico, Slovakia, Spain and Taiwan. Foundayo is FDA-approved for adults with obesity, or some adults with overweight who also have weight-related medical problems, and orforglipron was discovered by Chugai Pharmaceutical Co., Ltd. and licensed by Lilly in 2018.
Johnson & Johnson Moat Holds as Icotyde Estimate Raised to $4.5 Billion
Johnson & Johnson's economic moat rests on its ability to keep producing drugs rather than on any single drug, with the company's medical device business adding long-term hospital contracts that make switching suppliers closer to a retraining exercise than a purchasing decision. The company is worth about $638 billion and turns 29.19% of its $97.93 billion in revenue into operating profit, while return on equity reaches 25.74% and free cash flow ran to $16.89 billion over the past twelve months. Revenue grew 6.60% last quarter, and the balance sheet carries $49.04 billion of debt. On September 29, Bank of America raised its peak sales estimate for the oral psoriasis treatment Icotyde to $4.5 billion, from $2.4 billion previously, a test of whether the pipeline can replace revenue lost to patent expiries. Johnson & Johnson has spent years managing talc claims, and the shares now trade near 31 times trailing earnings but only about 21 times what analysts forecast for next year, on a yield of 2.02%.
Novo's Ozempic Cuts Cardiovascular Risk More Than Lilly's Mounjaro in Real-World Study
Novo Nordisk said new real-world data from its COMPETE SWITCH Cardiovascular study found that type II diabetes patients who increased their Ozempic dose had a lower observed risk of major adverse cardiovascular events than those who switched to Eli Lilly's Mounjaro. In the study, 67.2% of patients remained on Ozempic 1 mg within 365 days, 29.2% increased their dose to 2 mg and 3.6% switched to Mounjaro; by 720 days, 57.4% remained on semaglutide 1 mg, 36.9% had escalated to 2 mg and 5.7% had switched to Mounjaro. After adjustment for between-group differences, patients who increased their dose to Ozempic 2 mg had a statistically significant 6% lower risk of MACE than those who switched to Mounjaro, including doses of up to 15 mg, with MACE defined as all-cause death, heart attack and stroke. Novo cautioned that the study showed an association, not proof, that Ozempic 2 mg directly reduces cardiovascular risk more than Mounjaro, and that safety outcomes were not evaluated. Year to date, Novo shares have lost 22.2% against the industry's 14.9% growth.
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity ▲Competition
Aging Population › Chronic-Disease Pharma Franchises ▲Competition
Longevity & Life Extension › GLP-1 Healthspan Proxies ▲Competition
NVO · Technology · Positive Novo's own COMPETE SWITCH study found escalating to Ozempic 2 mg was associated with a statistically significant 6% lower MACE risk than switching to Mounjaro.
LLY · Competition · Negative Real-world COMPETE SWITCH data show patients on Ozempic 2 mg had a 6% lower MACE risk than those who switched to Lilly's Mounjaro, a competitive blow to Mounjaro.
Merck Q2 Revenue Rises 5.1% to $16.61 Billion, Beats Estimates
Merck reported second-quarter revenues of $16.61 billion, up 5.1% year on year and 2.1% above analysts' expectations, as the nine branded pharmaceuticals stocks tracked by the report collectively beat consensus revenue estimates by 6.6%. The company beat analysts' EPS estimates but missed analysts' full-year EPS guidance estimates, and its stock is up 16.2% since reporting, trading at $148.50. Among peers, Corcept Therapeutics posted the group's best quarter with revenues of $256.1 million, up 31.7% year on year and 21.6% above expectations, while Zoetis delivered the weakest performance with revenues of $2.47 billion, flat year on year and 1.5% below expectations. Collegium Pharmaceutical reported revenues of $199.9 million, up 6.3% year on year but 0.7% below expectations, and Pfizer reported revenues of $15.03 billion, up 2.6% year on year and 4.4% above expectations. As a group, share prices of the tracked companies have held steady, up 2.1% on average since the latest earnings results.
Eli Lilly Shares Rise After Foundayo Shows More Weight Loss
Eli Lilly shares edged 1% higher in morning trading Tuesday after new data showed its oral Foundayo treatment produced greater weight and blood-sugar reductions than oral semaglutide at higher doses. The analysis examined 17.2 mg of Foundayo, or orforglipron, in adults with type 2 diabetes, and at week 52 patients receiving the Lilly drug recorded 1.5% more body-weight reduction than those taking 25 mg of oral semaglutide. The blood-sugar measure A1C also moved in Lilly's favor, with the analysis showing a further 0.3% reduction compared with the semaglutide group. The findings were presented during the European Association for the Study of Diabetes meeting in Milan, where EASD materials listed additional studies involving the treatment. Lilly has been developing Foundayo across its diabetes program as competition in oral GLP-1 medicines expands, though the comparison comes from separate studies rather than a direct head-to-head trial.
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity ▲Competition
Aging Population › Chronic-Disease Pharma Franchises ▲Competition
Longevity & Life Extension › GLP-1 Healthspan Proxies ▲Competition
LLY · Technology · Positive New data showed Lilly's oral Foundayo produced greater weight and blood-sugar reductions than oral semaglutide at higher doses.
Lilly Says Higher-Dose Zepbound Widened Weight-Loss Lead Over Wegovy
Eli Lilly says higher doses of Zepbound may have widened its weight-loss advantage over Novo Nordisk's Wegovy. A new indirect analysis found that patients receiving Zepbound 15 mg and 10 mg had 4.5 percentage points and 3.2 percentage points more weight loss, respectively, over 72 weeks than patients taking high-dose Wegovy. According to Lilly, patients receiving Zepbound 15 mg were three times more likely to lose at least 20% of their body weight compared with those receiving Wegovy HD, and the difference was even more pronounced among people reaching larger weight-loss goals. Discontinuation rates because of adverse events were comparable across the Zepbound 10 mg, Zepbound 15 mg and Wegovy HD groups. Lilly cautioned that the results did not come from a direct head-to-head trial, comparing data from its Phase 3 SURMOUNT-1 study with Novo Nordisk's STEP UP studies. Novo shares were down about 1.3% in Tuesday premarket trading, while Lilly was up roughly 0.4%.
AbbVie Wins FDA Approval for Juvmo Parkinson's Treatment
AbbVie secured FDA approval for Juvmo, a once-daily Parkinson's treatment, though its shares slipped nearly 0.8% to $264.29. Juvmo works through D1/D5 dopamine receptors, a different target from older dopamine agonists. In the TEMPO-3 trial, patients taking it alongside levodopa gained 1.7 hours a day with symptoms controlled and no troublesome involuntary movement, compared with 0.6 hours for those given a placebo. AbbVie expects U.S. availability in October but has not disclosed Juvmo's price or a sales forecast, and nausea, dizziness and hallucinations are among the treatment concerns physicians must weigh. At $264.29, the stock sits 19.43% above its $221.28 GF Value estimate.
BofA Lifts J&J Target to $278, Sees Q3 EPS 12% Below Street
BofA Securities raised its price target on Johnson & Johnson to $278 from $263 while keeping a Neutral rating, lifting its forecasts for Icotyde and updating its model for recent in-process research and development charges. The new target applies 22x BofA's 2027 earnings estimate excluding those charges, up from 20.33x, which the firm tied to a sector re-rating for defensive stocks. For the third quarter, BofA expects sales of $25.5 billion, in line with consensus, and EPS of $2.53, 12% below the Street, with J&J having disclosed $0.64 of in-process R&D dilution for 2026, mostly falling in the third quarter. BofA models 6% revenue growth, with Pharma up 7% and MedTech up 4%, and points to IQVIA data showing four-week rolling prescriptions up 50% year over year for Tremfya in inflammatory bowel disease and 60% for Caplyta in major depressive disorder. Separately, J&J is reportedly in talks with Apollo Global Management over a potential sale of its orthopedics unit, which could be valued at nearly $20 billion.
Aging Population › Chronic-Disease Pharma Franchises ▲Capital
Aging Population › Medical Devices for the Aging Body Capital
JNJ · Capital · Positive BofA lifted its J&J price target to $278 on a defensive-sector re-rating and higher Icotyde forecasts.
BAC · Capital · Neutral BofA raised its J&J price target to $278 and updated its model, but the article gives no clear positive/negative read on BofA itself.
APO · Capital · Neutral Reportedly in talks with J&J over a potential ~$20B purchase of its orthopedics unit; deal is only exploratory.
Lilly Captures 70% of 700,000 New Medicare GLP-1 Patients
Eli Lilly CEO David Ricks said about 700,000 new seniors have started GLP-1 treatment since Medicare began covering obesity drugs in July, with roughly 70% using Lilly medicines. The temporary Medicare Bridge program lets eligible beneficiaries obtain obesity treatments for a $50 monthly co-pay, giving Zepbound and Foundayo access to a population that previously faced limited Medicare coverage. The early uptake matters because Zepbound generated $9.09 billion in revenue in the first half of 2026, up 60% year over year, while Mounjaro generated $18.61 billion, up 106%, with the two drugs together representing 65% of Lilly's total revenue in the period. Ricks said Zepbound remains popular among patients with higher body weight and more complications, while one-third of new oral GLP-1 patients are taking Foundayo, which Reuters reported had captured more than 30% of new U.S. oral obesity-drug patients. Medicare's Bridge program also covers Novo Nordisk's Wegovy and runs through December 2027, and Lilly has said higher volumes of Mounjaro and Zepbound have come with lower realized prices.
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity ▲Demand
Aging Population › Chronic-Disease Pharma Franchises ▲Demand
LLY · Demand · Positive Medicare Bridge coverage drove ~700,000 new seniors to GLP-1s, with roughly 70% using Lilly medicines like Zepbound and Foundayo
NVO · Demand · Neutral Medicare Bridge program also covers Novo Nordisk's Wegovy, but the article gives no specific uptake figures for Novo
Abbott and Berry Street Launch Exclusive Lingo Nutrition Coaching Partnership
Abbott and Berry Street announced an exclusive partnership to pair Abbott's Lingo continuous glucose monitor with Berry Street's insurance-covered registered dietitian support, helping consumers turn glucose insights into healthier behaviors. Under the deal, Berry Street and Lingo users can access registered dietitians specially trained on Lingo and continuous glucose monitors, receive personalized nutrition recommendations informed by their glucose trends, and meet virtually through one-to-one appointments. For the first time through this exclusive partnership, Berry Street users can obtain Lingo at a discounted price, receiving 15% off 4-week Lingo plans, while Lingo users are directed to sign up for Berry Street nutritionist services on the Lingo website and through Lingo email communications. Berry Street nutrition services are in-network with more than 1,250 health plans, with 96% of people paying no out-of-pocket costs, though coverage depends on the specific details of an individual's insurance plan. Abbott cited Centers for Disease Control and Prevention data showing more than 115 million US adults have prediabetes, yet approximately 80% are unaware they have it, and noted published research from the American Journal of Clinical Nutrition showing registered dietitian-led nutrition therapy can improve glucose control, weight management, cholesterol levels and other cardiometabolic markers. Olivier Ropars, divisional vice president of Abbott's Lingo business, said the combination of Lingo's biosensing technology with expert nutrition guidance can help people make informed nutrition and lifestyle decisions, while Berry Street chief executive officer and co-founder Noah Kotlove said continuous glucose insights plus registered dietitian expertise create a more personalized approach to nutrition.
Aging Population › Chronic-Disease Pharma Franchises Demand
ABT · Demand · Positive Exclusive partnership pairs Abbott's Lingo CGM with Berry Street dietitian services, expanding adoption and offering discounted Lingo plans to Berry Street users.
Berry Street · Demand · Positive Exclusive deal gives Berry Street users discounted Lingo access and directs Lingo users to its insurance-covered dietitian services, expanding its customer base.
TMAN targets 2030 revenue of 4 billion baht, growing 10-15% per year
T. Man Pharmaceutical Public Company Limited, or TMAN, has set a target of reaching 4 billion baht in total company revenue in 2030, along with a growth target of no less than 10-15% per year, above the industry's average growth rate of about 6-7% per year. Chief Executive Officer Praphon Thanachotiphan disclosed this at the event "TMAN opens Heaven Herb factory, driving Thailand toward a Wellness & Longevity Hub," saying the company is pushing into the over-the-counter and pharmacy market, targeting a top-10 market share from its current ranking of around 15th, and driving products into provincial hospitals, regional hospitals, medical schools, and private hospitals to move up to a top-10 market share in that group from its current ranking in the low 20s. In overseas markets, the company plans to push its main brand, Propolis, to become a regional brand, and will expand into 2-3 more overseas markets this year from the previous 7 countries, reaching nearly 10 countries within this year. It recently signed contracts with partners in South Korea and Indonesia, with revenue expected to begin being recognized in late 2026 or early 2027, and is in the process of penetrating the Philippines and Middle Eastern markets such as Oman. The company also aims to launch 15-20 new products per year, having already launched about 7-8 this year, which have consistently generated double-digit growth. For its anti-aging supplement product group, it targets a 5% share of total revenue within the next 3-5 years, and recently partnered with the mother-and-baby brand Lamoon to expand its consumer base into the mother-and-baby segment, with plans to bring in its research and development team to develop products to create a new S-Curve and build Longevity into a new growth engine. Within 5 years it will deliver approximately 15 products in the Science-backed Longevity Solutions group, and it targets revenue from that group at 5-10% of the portfolio in the next 3-5 years. It estimates Thailand's healthcare market value in 2026 at approximately 37.65 billion US dollars, expected to rise to approximately 61.38 billion US dollars in 2032, growing at an average of 8.49% per year.
Longevity & Life Extension › NAD+ & Cellular Energetics Demand
Aging Population › Chronic-Disease Pharma Franchises Demand
TMAN.BK · Demand · Positive TMAN targets 4 billion baht revenue by 2030 with 10-15% annual growth, expanding OTC/pharmacy and hospital channels, new overseas contracts in South Korea and Indonesia, and 15-20 new product launches per year.
AIA partners with BH to open wellness centre targeting high-net-worth clients in January 2027
AIA Thailand has partnered with VitalLife Wellness Centre, under Bumrungrad Hospital Public Company Limited, or BH, to open a wellness centre serving high-net-worth and high-spending clients, with services starting in January 2027. Mr Ekarat Thitimun, Chief Insurance Business Officer of AIA Thailand, said the partnership aims to offer medical technology and innovations backed by scientific evidence to design personalised health care and meet anti-ageing needs. The services cover in-depth health assessments, hormone balance and nutritional analysis, genetic factor evaluation, and health rehabilitation. Clients in the AIA Prestige Club, numbering more than 100,000, can access the services directly, and if complex diagnosis or treatment is required, they will be connected seamlessly to BH's network of specialist doctors. Assistant Professor Dr Phonkrit Teekakeerikul, Chief Executive Officer of VitalLife Wellness Centre and Esperance, and Chief Science Officer of BH and VitalLife Wellness Centre, said the partnership expands the scope of wellness from specialised services to an ecosystem of life that links health care with protection and long-term planning, with the goal of elevating Thailand to become a global wellness hub.
Aging Population › Home Healthcare & Hospice Demand
Aging Population › Chronic-Disease Pharma Franchises Demand
BH.BK · Demand · Positive BH's VitalLife Wellness Centre partners with AIA Thailand to open a wellness centre serving AIA's 100,000+ Prestige Club clients, expanding its customer base and referrals.
AIA Thailand · Demand · Positive AIA Thailand partners with BH's VitalLife to offer its Prestige Club members wellness services, adding a new offering for high-net-worth clients.
KKPS flags turning point in Thai public health, backs hospital and insurance stocks, recommends buying BH, BDMS, PR9, BCH, CHG
Kiatnakin Phatra Securities, or KKPS, believes Thailand's public health system is entering a major turning point, with pressure on the government budget set to become clearer by 2030 and likely to shift part of the burden of health expenses onto the private sector. Teerapol Udomvej, an analyst at KKPS, said the state currently bears about 450,000 to 500,000 million baht a year in public health costs, and even a partial transfer could channel more than 100,000 million baht in additional money into the private sector, or roughly 40% of the current revenue of listed private hospital groups. Meanwhile, demand for health insurance is likely to rise along with medical costs. Currently only 6.4% of Thais have private health insurance, and health insurance premiums grew by an average of about 8% a year between 2019 and 2025. For the hospital group, KKPS estimates that earnings passed their trough in the second quarter of 2026 and will gradually recover in the second half, after negative factors from stricter rules on insurance claims for children and a decline in Cambodian patients have already been reflected in the revenue base. Total hospital group revenue, which grew only 1-2% in the first half, accelerated to 6-7% in July and August on the seasonal spread of fever and COVID-19. On valuation, hospital stocks trade at a 2026 price-to-earnings ratio of about 19 times, below the regional average of roughly 30 times, while dividend yields have risen to 4-5% from about 1-2% previously. KKPS therefore raised its investment weighting for private hospitals to overweight and picked the group as a top sector, giving buy recommendations on the five hospitals it covers: Bumrungrad Hospital, or BH, with a target price of 230 baht; Bangkok Dusit Medical Services, or BDMS, with a target price of 23.50 baht; Praram 9 Hospital, or PR9, with a target price of 24.50 baht; Bangkok Chain Hospital, or BCH, with a target price of 13 baht; and Chularat Hospital, or CHG, with a target price of 2 baht.
Axsome Says AUVELITY Prescriptions Hit Record as Alzheimer's Launch Grows
Axsome Therapeutics said AUVELITY prescriptions are accelerating after its sales-force expansion and the drug's launch in Alzheimer's disease agitation, with weekly new-to-brand prescriptions reaching a record 3,800. Speaking at Morgan Stanley's Global Healthcare Conference, Chief Financial Officer Nick Pizzie said patients aged 65 and older now account for about 31% of new-to-brand prescriptions, up from roughly 19% before the indication's approval, and that agitation is the fastest-growing segment. Average weekly new-to-brand prescriptions were about 2,400 in the first quarter and 3,000 in the second quarter. Management reiterated its $8 billion long-term peak-sales outlook for AUVELITY, split evenly between $4 billion in major depressive disorder and $4 billion in Alzheimer's disease agitation, and reported 89% coverage of total covered lives, including 100% Medicare coverage. Pizzie said second-quarter selling, general and administrative expense of $208 million should be a reasonable reference point for the back half of the year, while research and development expense of $46 million is expected to rise modestly, and management expects revenue to grow faster than operating expenses on a very clear path toward positive cash flow and profitability.
Aging Population › Chronic-Disease Pharma Franchises ▲Demand
Biotech & Genomic Medicine › Neuroscience & Neurodegenerative ▲Demand
AXSM · Capital · Positive Management reiterated $8B peak-sales outlook and expects revenue to grow faster than opex on a path to positive cash flow and profitability.
AXSM · Demand · Positive AUVELITY prescriptions hit record 3,800 weekly new-to-brand as Alzheimer's agitation launch grows, with 65+ patients now 31% of new scripts.
Teva Study Finds Providers Prioritize Drowsiness Risk When Choosing Tardive Dyskinesia Treatment for Older Patients
Teva Pharmaceuticals announced new data showing that healthcare providers prioritize drowsiness risk, the duration of available long-term response data and drug-drug interaction profile when selecting a VMAT2 inhibitor for tardive dyskinesia in patients aged 55 and older. In a discrete choice experiment, 489 healthcare providers ranked somnolence risk, accounting for 26.8% to 36.2% of decision-making weight, and short-term symptom improvement, at 24.4% to 29.5%, as their top priorities, followed by dose formulation at 16.7% to 20.2% and drug-drug interaction risk at 14.4% to 17.3%. Applying those preferences across four patient profiles, AUSTEDO, also known as deutetrabenazine, had the highest predicted choice probability, driven mainly by somnolence risk, duration of long-term response data and drug-drug interaction. The findings were presented at Psych Congress, held September 15 to 19, 2026, in New Orleans. A separate interim analysis from the IMPACT-TD Registry found that among patients with probable tardive dyskinesia who remained untreated with any VMAT2 inhibitor for 24 months, roughly 89% to 96% experienced at least a mild global impact and 60% to 74% experienced moderate-to-severe impact, while 55% to 69% reported stable or worsening severity with no evidence of spontaneous resolution.
Aging Population › Chronic-Disease Pharma Franchises Competition
Biotech & Genomic Medicine › Neuroscience & Neurodegenerative Competition
TEVA · Demand · Positive Teva's study shows AUSTEDO has the highest predicted choice probability among VMAT2 inhibitors for tardive dyskinesia in older patients, supporting its adoption.
Eisai's Subcutaneous Leqembi Wins Health Ministry Approval, Enabling At-Home Dosing
Eisai and U.S. pharmaceutical giant Biogen announced on the 16th that the subcutaneous formulation of their Alzheimer's disease treatment lecanemab, sold under the brand name Leqembi, has received manufacturing and marketing approval from the Ministry of Health, Labour and Welfare. The product, named Leqembi Subcutaneous Injection 250mg Pen, can be administered in about 15 seconds per pen, with two pens used per dose. Until now, patients needed intravenous infusions at a hospital once every two weeks, but the subcutaneous formulation allows once-weekly self-administration at home, though doctor visits will still be required for prescriptions and safety checks. Following deliberation and approval by the Central Social Insurance Medical Council, prescriptions are expected to begin between mid-November and mid-December. This is the third country to approve the subcutaneous version, after the United States and China.
Biotech & Genomic Medicine › Neuroscience & Neurodegenerative ▲Regulation
Aging Population › Chronic-Disease Pharma Franchises ▲Regulation
4523.JP · Regulation · Positive Eisai's subcutaneous Leqembi receives Japanese manufacturing and marketing approval, enabling at-home dosing.
BIIB · Regulation · Positive Subcutaneous Leqembi, co-developed with Eisai, wins Japanese health ministry approval, expanding the drug's administration options.
Eli Lilly Hits $1 Trillion Market Cap as 24/7 Wall St. Sets $1,220 Price Target
Eli Lilly has crossed into trillion-dollar territory, trading at $1,123.98 with a market capitalization of $1.002 trillion, and 24/7 Wall St. rates the stock a buy with a 12-month price target of $1,220.42, implying 8.58% upside at 90% confidence. The company's second-quarter 2026 revenue reached $22.974 billion, up 47.67% year over year, with earnings per share of $8.38 beating consensus by 27.27%, and management raised full-year revenue guidance to $85 billion to $87 billion. Mounjaro alone posted $9.94 billion, up 91% year over year, while the incretin franchise generated roughly $14.87 billion of the quarter's revenue. The bull case targets $1,381.62, a 22.92% gain, driven by retatrutide's planned BLA submission in the first quarter of 2027, the oral GLP-1 Foundayo's expansion to 36,000 prescribers, and the Medicare GLP-1 Bridge Program opening access for 20 million eligible Americans at $50 per month. The bear case takes shares to $1,045.34, a 7% decline, citing realized prices that fell 13% in the second quarter, $2.78 billion in acquired IPR&D charges, and net insider selling. Lilly's forward price-to-earnings ratio of 24 compares with 14 for Novo Nordisk, which grew quarterly revenue just 2.1%, and 16 for Merck, whose quarterly earnings shrank 19.3% year over year.
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity ▲Demand
Aging Population › Chronic-Disease Pharma Franchises ▲Demand
LLY · Capital · Positive Crossed $1 trillion market cap with Q2 2026 revenue up 47.67%, EPS beating consensus by 27.27%, and raised full-year guidance, plus a $1,220 buy price target.
LLY · Demand · Positive Mounjaro posted $9.94B (up 91% YoY) and the incretin franchise drove ~$14.87B of quarterly revenue, with Foundayo expanding to 36,000 prescribers and Medicare opening access to 20 million Americans.
NVO · Competition · Neutral Novo Nordisk is mentioned only as a comparison, with quarterly revenue growth of just 2.1% versus Lilly's 47.67%.
Medical Costs Reach 49.2 Trillion Yen: Explaining the Increase in High-Cost Medical Care Ceilings and System Reforms
According to the latest data from the Ministry of Health, Labour and Welfare, Japan's total medical costs reached 49.2 trillion yen, an increase of about 1.3 trillion yen from the previous year. The growth rate was 2.6 percent. Although the number of days of medical treatment decreased, the rise in medical costs per day pushed up the total. Medical costs for those aged 75 and over were 20.3 trillion yen, accounting for 41.3 percent of the total, with per-person costs of 989,000 yen, about 3.8 times that of those under 75. From August 2026, the high-cost medical care system will be revised, raising the ceiling on out-of-pocket payments while introducing a new annual cap for long-term patients. Furthermore, under the medical insurance system reform law enacted in fiscal 2026, revisions to benefits for over-the-counter similar drugs, reflection of financial income of late-stage elderly, in-kind provision of childbirth costs, and expansion of insurance premium reductions for households raising children are planned.
Roche Gets FDA Clearance for Alzheimer's Blood Test
Roche Holding announced a collaboration with Treeline Biosciences to study combination immunotherapies for B-cell lymphomas, and received FDA clearance for its Elecsys pTau217 blood test, the first single biomarker assay to help rule in and rule out amyloid pathology in Alzheimer's disease. The test is intended to support earlier and more accessible Alzheimer's diagnostic assessments. Roche, a pharmaceuticals and diagnostics group with a CHF285.2 billion market cap, is expanding its oncology pipeline through partnerships and its diagnostics portfolio with neurology assays. The lymphoma partnership and the blood test clearance align with Roche's strategy of combining pipeline breadth and diagnostics depth, though the company faces competition from Novartis, Bristol Myers Squibb, Abbott, and Siemens Healthineers.
Eastspring: Healthcare Offers Defensive Growth Amid High Bond Yields
Eastspring Asset Management (Thailand) views the Healthcare sector as one of the most attractive investment opportunities amid a rotation of funds out of technology and AI stocks, as bond yields remain elevated. The firm notes that healthcare stocks have strong fundamentals and a trend of continued growth, or what is known as Defensive Growth, while institutions have been increasing their allocation to the sector. Between May 26 and August 25, 2026, the XLV Healthcare index rose 18.65%, while the Technology sector posted a negative return of 0.67%, and the MSCI World gained only 3.32%. The US 10-year yield stood at approximately 4.64%, up from 4.0% at the end of February, and could rise further on inflation concerns, which may continue to pressure technology stocks. Eastspring points out that Healthcare combines defensive characteristics, demand from an aging society, and growth, with S&P 500 Healthcare EPS expected to grow 21.3% in 2027, higher than the S&P 500's 11.94%. The BofA Global Fund Manager Survey for July 2026 found that Healthcare was the sector where fund managers increased their allocations the most. For interested investors, the ES-HEALTHCARE fund invests through the Janus Henderson Global Life Sciences Fund in life sciences stocks globally.
TUI Launches Longevity Portfolio from Tuna with 3 Ingredients, Tapping into Aging Trend
Thai Union Ingredients (TUI) has launched its Longevity portfolio at Vitafoods Asia 2026, presenting innovative solutions from three tuna-derived ingredients: DHA fish oil, collagen, and bio-calcium, which support brain function, skin health, and bone health, backed by scientific research. The company aims to generate at least $30 million in revenue from ThalaCol™ within five years and increase premium-grade omega-3 oil sales with an average annual growth rate of over 50% by 2030. This launch comes amid demographic shifts in Asia-Pacific, with UNFPA projecting that the population aged 60 and above will triple to 1.3 billion by 2050. Meanwhile, a 2025 McKinsey survey found that over 60% of consumers prioritize healthy aging. The three ingredients are developed from tuna by-products, including fish heads, skin, and bones, and are produced at facilities in Germany, Samut Sakhon, and Songkhla, supporting Thai Union's SeaChange® 2030 sustainability strategy.
Biotech & Genomic Medicine › Tools, Diagnostics & CDMO ▲Supply
Aging Population › Chronic-Disease Pharma Franchises ▲Demand
Thai Union Ingredient PCL · Demand · Positive TUI launched its Longevity portfolio of three tuna-derived ingredients, targeting $30M ThalaCol revenue in five years and >50% annual omega-3 growth by 2030.
Thai Union Ingredient Launches Longevity Portfolio from Tuna
Thai Union Ingredient (TUI), part of Thai Union Group Public Company Limited (TU), has launched its Longevity portfolio, an innovative range of ingredients derived from tuna, including DHA fish oil, collagen, and bio-calcium. These nutrients support brain function, skin health, and bone health, backed by scientific research and a tuna supply chain managed from source to end product. The launch comes as the Asia-Pacific region undergoes demographic shifts, with the United Nations Population Fund (UNFPA) projecting that the population aged 60 and above in the region will triple from 2010 to about 1.3 billion by 2050, accounting for one in four people in the region. Meanwhile, a 2025 McKinsey survey found that over 60% of consumers rank healthy aging as their top priority, and younger generations are increasingly proactive about their health. Ms. Leena Uabamrungjit, Senior Director of TU's Ingredient Business Group, said that most suppliers in the Longevity market specialize in specific areas rather than offering comprehensive solutions. The company has therefore developed a platform that brings together high-quality marine ingredients in one place, backed by a full supply chain, traceability systems, and research collaborations with leading universities. The three ingredients are: UniQ®OMEGA, a purified tuna oil rich in DHA that improves focus by 42% and working memory by 33%; ThalaCol™, a tuna collagen peptide that increases skin hydration by 68%, dermal density by 26%, and elasticity by 16%; and UniQ®BONE, a tuna bio-calcium that strengthens bone structure by 39%. These are developed from by-products of tuna processing—heads, skin, and bones—which most seafood processors cannot utilize. TU transforms them into high-value food ingredients at its tuna oil refinery in Germany, collagen production facility in Samut Sakhon, and calcium powder plant in Songkhla. The company aims to generate at least $30 million in revenue from ThalaCol™ within five years and to grow premium omega-3 oil sales at a compound annual growth rate (CAGR) of over 50% by 2030.
Aging Population › Chronic-Disease Pharma Franchises ▲Supply
Thai Union Ingredient PCL · Technology · Positive Thai Union Ingredient launched its Longevity portfolio of tuna-derived ingredients with documented efficacy results.
TU.BK · Technology · Positive Thai Union Group's ingredient unit launched the Longevity portfolio of tuna-derived DHA, collagen, and bio-calcium ingredients backed by research.
200,000 Medicare users join Bridge obesity drug program
Medicare's Bridge program, which offers obesity drugs for a flat $50 per month, has enrolled at least 200,000 participants within its first 60 days, according to Jeremy Shane of the USC Leonard D. Schaeffer Institute. The program, launched July 1, 2026, and running through December 2027, targets Medicare Part D enrollees with conditions like high blood pressure or diabetes who otherwise lack weight-loss drug coverage. Experts say the rapid uptake signals significant pent-up demand, though Medicare originally estimated about 4 million recipients might qualify. An independent KFF analysis suggests 10% to 25% of eligible enrollees are using the program, costing Medicare between $1.3 billion and $3.3 billion, with costs potentially rising to $6.7 billion to $10 billion if 50% to 75% enroll. Healthcare analysts warn of an "affordability cliff" when the program ends in 2027, potentially driving patients to unregulated alternatives, while others highlight long-term benefits like reduced hospitalizations and cardiovascular events. Medicare recipients can check eligibility at Medicare.gov/glp1bridge or call 1-800-MEDICARE.
Taiwan Faces Demographic Crisis, Population Expected to Drop 48% to 12.15 Million by 2075
Bloomberg reports that Taiwan's population may decline to about 12.15 million by 2075, a drop of roughly 48% from 2026 levels, amid a continued decrease in births and young population, while the number of elderly rises significantly, posing long-term challenges to the labor market, economy, and defense capabilities. Estimates from Taiwan's National Development Council (NDC), based on household registration data, indicate that the working-age population will shrink by nearly two-thirds over the next 50 years. By 2075, the population aged 0-14 will be only 585,000, the working-age population (15-64) will be about 5.13 million, and those aged 65 and above will reach 6.43 million, meaning the elderly will outnumber the working-age population and account for more than half of the total population. These figures reflect risks after the population peaked at 23.6 million in 2019, and could also affect Taiwan's security, as the military still relies partly on conscription amid threats from China.
